FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2139777788> ?p ?o ?g. }

• W2139777788 endingPage "70" @default.
• W2139777788 startingPage "61" @default.
• W2139777788 abstract "1. Investigated were the effects of a new oral antidiabetic drug, troglitazone, and its three metabolites and antidiabetic drug candidates pioglitazone and rosiglitazone on xenobiotic oxidations catalyzed by nine recombinant human cytochrome P450 (P450 or CYP) enzymes and by human liver microsomes. 2. Troglitazone (5 muM) significantly inhibited CYP2C8-dependent paclitaxel 6alpha- hydroxylation and CYP2C9-dependent S-warfarin 7-hydroxylation. On the other hand, pioglitazone and rosiglitazone (50 muM) only slightly inhibited these xenobiotic oxidation activities catalyzed by CYP2C enzymes. 3. The inhibitory potential of troglitazone (50% inhibition concentration, IC50) was ~5 muM for drug oxidations catalyzed by CYP2C9 and CYP2C8 and C20 muM for activities catalyzed by CYP2C19 and CYP3A4 respectively. For the three metabolites of troglitazone tested, a quinone-type metabolite (M3) was the most potent inhibitor for CYP2C enzymes, followed by a sulphate conjugate (M1); effects of a glucuronide (M2) were very weak. The inhibitory effects of the parent drug were more potent than those of metabolites. Troglitazone and M3 inhibited P450 activities mainly through a competitive manner with Ki=0.2-1.7 muM and 1.4-8.8 muM respectively. 4. In three human liver microsomes, troglitazone and its metabolites also inhibited paclitaxel 6alpha-hydroxylation, S-warfarin 7-hydroxylation, S-mephenytoin 4'-hydroxylation, and testosterone 6beta-hydroxylation with similar IC50, as observed for the recombinant P450 enzyme systems. 5. These results suggest that xenobiotic oxidations by P450 enzymes are more substantially affected by troglitazone and its metabolites than pioglitazone or rosiglitazone, and that drug interactions may be of much importance to understand the basis for the pharmacological and toxicological actions of this new oral antidiabetic drug." @default.
• W2139777788 created "2016-06-24" @default.
• W2139777788 creator A5001851785 @default.
• W2139777788 creator A5032660436 @default.
• W2139777788 creator A5071569408 @default.
• W2139777788 creator A5077221711 @default.
• W2139777788 creator A5078922881 @default.
• W2139777788 creator A5089297113 @default.
• W2139777788 date "2000-01-01" @default.
• W2139777788 modified "2023-09-27" @default.
• W2139777788 title "In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone" @default.
• W2139777788 cites W1951469402 @default.
• W2139777788 cites W1987954745 @default.
• W2139777788 cites W1990907964 @default.
• W2139777788 cites W2003856834 @default.
• W2139777788 cites W2009345128 @default.
• W2139777788 cites W2064498106 @default.
• W2139777788 cites W2085367477 @default.
• W2139777788 cites W2088524561 @default.
• W2139777788 cites W2091151200 @default.
• W2139777788 doi "https://doi.org/10.1080/004982500237820" @default.
• W2139777788 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10659951" @default.
• W2139777788 hasPublicationYear "2000" @default.
• W2139777788 type Work @default.
• W2139777788 sameAs 2139777788 @default.
• W2139777788 citedByCount "56" @default.
• W2139777788 countsByYear W21397777882012 @default.
• W2139777788 countsByYear W21397777882014 @default.
• W2139777788 countsByYear W21397777882015 @default.
• W2139777788 countsByYear W21397777882017 @default.
• W2139777788 countsByYear W21397777882020 @default.
• W2139777788 crossrefType "journal-article" @default.
• W2139777788 hasAuthorship W2139777788A5001851785 @default.
• W2139777788 hasAuthorship W2139777788A5032660436 @default.
• W2139777788 hasAuthorship W2139777788A5071569408 @default.
• W2139777788 hasAuthorship W2139777788A5077221711 @default.
• W2139777788 hasAuthorship W2139777788A5078922881 @default.
• W2139777788 hasAuthorship W2139777788A5089297113 @default.
• W2139777788 hasConcept C109650736 @default.
• W2139777788 hasConcept C134018914 @default.
• W2139777788 hasConcept C170493617 @default.
• W2139777788 hasConcept C181199279 @default.
• W2139777788 hasConcept C185592680 @default.
• W2139777788 hasConcept C187345961 @default.
• W2139777788 hasConcept C202751555 @default.
• W2139777788 hasConcept C2777180221 @default.
• W2139777788 hasConcept C2777477808 @default.
• W2139777788 hasConcept C2777752497 @default.
• W2139777788 hasConcept C2778150266 @default.
• W2139777788 hasConcept C2778384471 @default.
• W2139777788 hasConcept C2780152017 @default.
• W2139777788 hasConcept C2781109383 @default.
• W2139777788 hasConcept C3946865 @default.
• W2139777788 hasConcept C526171541 @default.
• W2139777788 hasConcept C55493867 @default.
• W2139777788 hasConcept C555293320 @default.
• W2139777788 hasConcept C86803240 @default.
• W2139777788 hasConcept C87644729 @default.
• W2139777788 hasConcept C98274493 @default.
• W2139777788 hasConceptScore W2139777788C109650736 @default.
• W2139777788 hasConceptScore W2139777788C134018914 @default.
• W2139777788 hasConceptScore W2139777788C170493617 @default.
• W2139777788 hasConceptScore W2139777788C181199279 @default.
• W2139777788 hasConceptScore W2139777788C185592680 @default.
• W2139777788 hasConceptScore W2139777788C187345961 @default.
• W2139777788 hasConceptScore W2139777788C202751555 @default.
• W2139777788 hasConceptScore W2139777788C2777180221 @default.
• W2139777788 hasConceptScore W2139777788C2777477808 @default.
• W2139777788 hasConceptScore W2139777788C2777752497 @default.
• W2139777788 hasConceptScore W2139777788C2778150266 @default.
• W2139777788 hasConceptScore W2139777788C2778384471 @default.
• W2139777788 hasConceptScore W2139777788C2780152017 @default.
• W2139777788 hasConceptScore W2139777788C2781109383 @default.
• W2139777788 hasConceptScore W2139777788C3946865 @default.
• W2139777788 hasConceptScore W2139777788C526171541 @default.
• W2139777788 hasConceptScore W2139777788C55493867 @default.
• W2139777788 hasConceptScore W2139777788C555293320 @default.
• W2139777788 hasConceptScore W2139777788C86803240 @default.
• W2139777788 hasConceptScore W2139777788C87644729 @default.
• W2139777788 hasConceptScore W2139777788C98274493 @default.
• W2139777788 hasIssue "1" @default.
• W2139777788 hasLocation W21397777881 @default.
• W2139777788 hasLocation W21397777882 @default.
• W2139777788 hasOpenAccess W2139777788 @default.
• W2139777788 hasPrimaryLocation W21397777881 @default.
• W2139777788 hasRelatedWork W1777842366 @default.
• W2139777788 hasRelatedWork W2052588257 @default.
• W2139777788 hasRelatedWork W2078510487 @default.
• W2139777788 hasRelatedWork W2092063638 @default.
• W2139777788 hasRelatedWork W2116139281 @default.
• W2139777788 hasRelatedWork W2139777788 @default.
• W2139777788 hasRelatedWork W2142619379 @default.
• W2139777788 hasRelatedWork W2473315520 @default.
• W2139777788 hasRelatedWork W2341990973 @default.
• W2139777788 hasRelatedWork W3021177496 @default.
• W2139777788 hasVolume "30" @default.
• W2139777788 isParatext "false" @default.
• W2139777788 isRetracted "false" @default.

• next